Natera’s Signatera ctDNA test will be used as a minimal residual disease endpoint in Aveta Biomics’ Phase 3 trial of APG-157 in locally advanced head and neck squamous cell carcinoma. The study will enroll up to 826 patients across resectable and unresectable cohorts, with Signatera supporting both clinical response assessments and regulatory-aligned molecular data.